- Trial phase
- Approved
- Time to market
- Already approved and commercialized (US launch March 2024)
- Why 4/10
- AGAMREE is already FDA-approved (Oct 2023) and commercially available, with no pending PDUFA or pivotal readout for new indications in the next ~12 months. The SUMMIT long-term safety registry is observational and not a stock-moving binary. AGAMREE is ~20% of Catalyst's revenue mix and growing, but the company's defining binary events (approval, launch) have passed.
For a non-medical investor, AGAMREE is a commercial-stage asset already contributing meaningful revenue growth ($117M in 2025, guiding $140-150M for 2026). There's no binary FDA catalyst ahead, so the stock moves on quarterly sales execution and overall company performance. Watch quarterly AGAMREE revenue growth rates and any news about label expansion studies (DMD is the only approved indication). Multiple analysts downgraded CPRX to Hold/Neutral recently, suggesting the easy money from the approval catalyst is behind it.
Price Chart
Executive Summary
AGAMREE (vamorolone) is a first-in-class dissociative corticosteroid approved by the FDA in October 2023 for Duchenne Muscular Dystrophy (DMD) in patients aged 2 years and older. Catalyst Pharmaceuticals (NASDAQ: CPRX) holds exclusive North American commercialization rights. The drug generated $117.1M in US net revenue in 2025 (up 154% YoY), and Catalyst guides $140-150M for 2026. It competes against standard corticosteroids (prednisone, deflazacort/Emflaza) with a differentiated safety profile. Since AGAMREE is already approved and commercializing with no imminent regulatory binary, the stock catalyst shifts to commercial execution and potential future label expansion. CPRX has been downgraded by multiple analysts recently, and the stock trades near its 52-week high.
How It Works
AGAMREE is a "dissociative steroid", a new type of corticosteroid designed to keep the muscle-strengthening and anti-inflammatory benefits of traditional steroids (like prednisone) while reducing the nasty side effects. In Duchenne muscular dystrophy, it helps boys maintain muscle function and delay loss of the ability to walk, but with less stunting of growth and better bone health compared to standard steroids.
Trial Status
AGAMREE was FDA-approved on October 26, 2023 based on the pivotal Phase 2b VISION-DMD study plus open-label extension safety data. A post-marketing SUMMIT registry study (NCT06564974) is actively recruiting to observe long-term safety and quality-of-life outcomes in DMD patients over 5 years. Long-term data presented at MDA 2026 confirmed comparable efficacy to traditional corticosteroids for up to 8 years with meaningful safety advantages (normal growth preserved).
The Two-Sided Case
Upcoming Catalysts
- Quarterly earnings reports, key metric is AGAMREE revenue growth trajectory vs guidance of $140-150M for 2026
- Potential label expansion studies for other indications (Catalyst holds license for additional indications beyond DMD)
- Long-term SUMMIT registry study data readouts
- European market expansion updates (Santhera leading rest-of-world commercialization)
Source Filing
The SecBot filing or press-release report that triggered this drug report:
CATALYST PHARMACEUTICALS, INC. DEFA14A CPRX ·Originating report